|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, March 24, 2016 ) Leishmaniasis (Kala-Azar) - Pipeline Review, H1 2015 Size and Share Published in 2015-06-10 Available for US$ 2000 at Researchmoz.us
Description
Global Markets Directs, Leishmaniasis (Kala-Azar) Pipeline Review, H1 2015, provides an overview of the Leishmaniasis (Kala-Azar)s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Leishmaniasis (Kala-Azar), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Leishmaniasis (Kala-Azar) and special features on late-stage and discontinued projects.
Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Download Sample of this Report at: http://www.researchmoz.us/enquiry.php?type=S&repid=297830
Scope
The report provides a snapshot of the global therapeutic landscape of Leishmaniasis (Kala-Azar)
The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved in the therapeutics development for Leishmaniasis (Kala-Azar) and enlists all their major and minor projects
The report summarizes all the dormant and discontinued pipeline projects
A review of the Leishmaniasis (Kala-Azar) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
A detailed assessment of monotherapy and combination therapy pipeline projects
Coverage of the Leishmaniasis (Kala-Azar) pipeline on the basis of target, MoA, route of administration and molecule type
Latest news and deals relating related to pipeline products
Reasons to buy
Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop strategic initiatives by understanding the focus areas of leading companies
Identify and understand important and diverse types of therapeutics under development for Leishmaniasis (Kala-Azar)
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Devise corrective measures for pipeline projects by understanding Leishmaniasis (Kala-Azar) pipeline depth and focus of Indication therapeutics
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Make an Enquiry: http://www.researchmoz.us/enquiry.php?type=E&repid=297830
Table of Content
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Leishmaniasis (Kala-Azar) Overview 10
Therapeutics Development 11
Pipeline Products for Leishmaniasis (Kala-Azar) - Overview 11
Pipeline Products for Leishmaniasis (Kala-Azar) - Comparative Analysis 12
Leishmaniasis (Kala-Azar) - Therapeutics under Development by Companies 13
Leishmaniasis (Kala-Azar) - Therapeutics under Investigation by Universities/Institutes 14
Leishmaniasis (Kala-Azar) - Pipeline Products Glance 15
Clinical Stage Products 15
Early Stage Products 16
Leishmaniasis (Kala-Azar) - Products under Development by Companies 17
Leishmaniasis (Kala-Azar) - Products under Investigation by Universities/Institutes 19
Leishmaniasis (Kala-Azar) - Companies Involved in Therapeutics Development 20
Browse All Pharmaceutical Market Research Reports at: http://www.researchmoz.us/pharmaceutical-market-reports-38.html
About ResearchMoz
ResearchMoz is the world’s fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives.
Contact Us:
ResearchMoz
Mr. Nachiket Ghumare, +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
sales@researchmoz.us <||>rnhttp://www.researchmoz.us/
For More Report Click Here @ http://www.prweb.com/search.aspx?search-releases=researchmoz&hitsPerPage=20
Researchmoz Global Pvt.Ltd
Researchmoz
+1-518-621-2074
sales@researchmoz.us
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
